国家自然科学基金面上项目（2014）：建立利用激光显微切割联合质谱蛋白质组学技术鉴定系统性淀粉样变患者中致淀粉样变性蛋白类型的方法

国家自然科学基金面上项目（2016）：POEMS综合征中高水平血管内皮生长因子A的异构体组成及其调控机制

国家自然科学基金面上项目（2020）：AL-LC通过促进心肌细胞自噬导致轻链型心肌淀粉样变发病的机制研究

北京自然科学基金面上项目（2014）：POEMS综合征患者中高血清VEGF的细胞来源及分子机制研究

北京自然科学基金面上项目（2018）：ASB15基因在轻链型淀粉样变发病中的意义

首都发展专项基金（2018）：比较化疗联合或不联合多西环素治疗晚期原发性轻链型淀粉样变患者的前瞻性、多中心、随机对照研究

Zhang L*, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, Zhou DB, Zhong DR, Fajgenbaum DC, Li J#. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 2019;133(16):1720-1728. 

Zhao H*, Huang XF, Gao XM, Cai H, Zhang L, Feng J, Cao XX, Zhou DB, Li J#. What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia. 2019;33(4):1023-1029.

Li J*, Duan MH*, Wang C*, Huang XF, Zhang W, Cao XX, Zhu TN, Zhuang JL, Han B, Cai H, Cai HC, Zhou DB#. Impact of pre-transplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome.Leukemia. 2017;31(6):1375-1381.

Wang C*, Huang XF, Cai QQ, Cao XX, Duan MH, Cai H, Zhou DB, Li J#. Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome. Leukemia. 2017;31(1):100-106.

Li J*, Zhang W, Jiao L, Duan MH, Guan HZ, Zhu WG, Tian Z, Zhou DB#. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood. 2011; 117(24):6445-9.

Li J*, Tian Z, Zheng HY, Zhang W, Duan MH, Liu YT, Cao XX, Zhou DB#. Pulmonary hypertension in POEMS syndrome. Haematologica. 2013;98(3):393-8.

Li J*, Zhou DB#. New advances in the diagnosis and treatment of POEMS syndrome. Br J Haematol. 2013;161(3):303-15.

Zhang C*, Huang X, Li J#. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role? Blood Reviews. 2017;31(4):261-270.

Li J*, Huang XF*, Cai QQ, Wang C, Cai H, Zhao H, Zhang L, Cao XX, Gale RP, ZhouDB#. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol. 2018;93(6):803-809.

Shen KN*, Zhang CL*, Tian Z, Feng J, Wang YN, Sun J, Zhang L, Cao XX, Zhou DB, Li J#. Bortezomib based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. Amyloid. 2019; 26(2):66-73.

Jian-hua Han, Ji-nuo Wang*, Yue-lun Zhang*, Xin-xin Cao, Dao-bin Zhou, Teng-da Xu#, Wei Su#, Jian Li#. Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China. Blood Cancer Journal. 2020; 10:34.

Hao Zhao, Hao Cai*, Chen Wang, Xu-fei Huang, Xin-xin Cao, Lu Zhang, Dao-bin Zhou, Jian Li#. Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome. Blood Cancer Journal. 2018; 8:37

Xu-Fei Huang, Sun Jian*, Jun-Liang Lu*, Kai-Ni Shen, Jun Feng, Cong-Li Zhang, Zhuang Tian, Jia-Li Wang, Wan-Jun Lei, Xin-Xin Cao, Dao-bin Zhou, Zhi-Yong Liang#, Jian Li#. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. Amyloid. 2020; 27(1):36-44.